Pfizer Inc PFE
News
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Moderna wins second product approval with RSV vaccine
Pfizer Study Shows Lorbrena Reduces Chances of Lung Cancer Getting Worse
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
New U.S. bird-flu case is first with respiratory symptoms, CDC says
HSBC's new offices are coaxing hybrid workers into the office more frequently
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
Pfizer to Cut Costs in Multi-Year Effort — Update
Pfizer to Cut Costs in Multi-Year Effort
China-Based Asymchem Laboratories Will Operate Former Pfizer Manufacturing Facility in UK
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion — Update
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit — Update
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
France Secures Billions at Foreign Investment Summit
Pfizer Agrees to Settle 10,000 Zantac Lawsuits Over Alleged Cancer Risks, Bloomberg Reports
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Pfizer Names Andrew Baum Chief Strategy, Innovation Officer